Will Eton Pharmaceuticals stock go up?

According to Danelfin AI, Eton Pharmaceuticals has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (55.31%) is +4.49% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Eton Pharmaceuticals stock?

The Eton Pharmaceuticals target price is $44.53 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Eton Pharmaceuticals stock right now?

Eton Pharmaceuticals has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (55.31%) is +4.49% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Eton Pharmaceuticals stock is a good buy .

Is Eton Pharmaceuticals undervalued right now?

Based on analysts, the average price target upside for Eton Pharmaceuticals is +21.51% (1Y). According to Danelfin AI, Eton Pharmaceuticals has today an AI Score of 6/10 (Hold Rating).

What was the price range of Eton Pharmaceuticals stock over the past 12 months?

The Eton Pharmaceuticals stock price range over the past 12 months has been $13.5 - $36.73.

What is going on with Eton Pharmaceuticals stock in the last 3 months?

The Eton Pharmaceuticals stock performance in the last quarter has been +48.50%.

Does Eton Pharmaceuticals offer dividend payments?

No, Eton Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Eton Pharmaceuticals?

Eton Pharmaceuticals's market cap is $1B, as of 2026-07-02 08:00.

When is the next ETON earnings report date?

ETON will publish its next earnings report on 2026-05-14.

Eton Pharmaceuticals Inc (ETON) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ETON AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Eton Pharmaceuticals Inc today receives an AI Score of 6/10, which translates to a Hold rating. The stock has a 55% probability of outperforming the market in the next 3 months, which is 4% higher than the average probability of any stock (51%). Key positive contributors include the long tail of fundamentals impact (+2.16%), the Pharmaceuticals industry (+1.31%), and the 180-day chart pattern (+0.90%). On the negative side, the 504-day chart pattern (-0.55%), the Fear & Greed Index at 31 (-0.55%), and the Plus Directional Indicator (+DI, 90d) in the top 20% (-0.46%) are the top detractors. Notable data points include Operating Cash Flow in the top 50% (+0.50%), which supports the positive outlook, while Tangible Shareholders' Equity in the bottom 20% (-0.43%) and Net PP&E in the bottom 10% (-0.40%) weigh on the probability. The stock's institutional ownership is in the top 50% at 65.18% (+0.24%), indicating some confidence. Overall, the mix of positive fundamentals and industry tailwinds is partially offset by weak balance sheet metrics and bearish technical signals, resulting in a balanced HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment+1.59%
How analysts and the market view the stock
Momentum+1.41%
Direction and strength of recent price movements
Valuation+1.00%
How the stock is priced relative to its fundamentals
Earnings Quality+0.50%
Stability and reliability of reported earnings
Size & Liquidity+0.22%
Company size and trading liquidity

Volatility-0.22%
How much the stock price tends to fluctuate

ETON probability advantage of beating the market (3M):

+4.49%

Technical

Eton Pharmaceuticals (ETON) has a Technical Score of 6/10 because, according to only technical analysis, it has a probability advantage of +1.08% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of ETON (51.72%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
ETON probability advantage of beating the market (only technical, 3M)+1.08%
ETON probability of beating the market (3M)51.72%

ETON probability advantage of beating the market (only technical, 3M): +1.08%

The AI-powered technical analysis of Eton Pharmaceuticals (ETON) is only based on the 31 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ETON:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+5.63%
Technical	Upgrade to Pro to unlock	+2.97%
Technical	Upgrade to Pro to unlock	-2.86%
Technical	Upgrade to Pro to unlock	-2.79%
Technical	Upgrade to Pro to unlock	-2.40%
Technical	Upgrade to Pro to unlock	-2.22%
Technical	Upgrade to Pro to unlock	+2.20%
Technical	Upgrade to Pro to unlock	+1.55%
Technical	Upgrade to Pro to unlock	-1.54%
Technical	Upgrade to Pro to unlock	-1.45%
Technical	Upgrade to Pro to unlock	+1.20%
Technical	Upgrade to Pro to unlock	-1.15%
Technical	Upgrade to Pro to unlock	-1.15%
Technical	Upgrade to Pro to unlock	+1.10%
Technical	Upgrade to Pro to unlock	-1.10%

Rest of Alpha Signals: +3.10%

ETON probability advantage of beating the market (only technical, 3M)Total:+1.08%
ETON Technical Score

Significant changes Vs previous day

ETON Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$36.65
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

ETON Proven Hold Signal & Price Forecast

This is the price chart for ETON from January 1, 2026 until today. The chart indicates, in yellow, the 102 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ETON Average Past Performance & Win Rate

Three months after its 1246 Hold signals since July 2026, ETON had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1246 Past ETON Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+51.70%
Average Alpha				+35.98%
Win Rate (% Positive Perf.)				57.06%
% Positive Alpha				44.53%

ETON Frequently Asked Questions

Will Eton Pharmaceuticals stock go up?
According to Danelfin AI, Eton Pharmaceuticals has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (55.31%) is +4.49% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Eton Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Eton Pharmaceuticals stock right now?
Is Eton Pharmaceuticals undervalued right now?
What was the price range of Eton Pharmaceuticals stock over the past 12 months?
What is going on with Eton Pharmaceuticals stock in the last 3 months?
Does Eton Pharmaceuticals offer dividend payments?
What is the current market capitalization of Eton Pharmaceuticals?
When is the next ETON earnings report date?

Eton Pharmaceuticals Inc Company Profile

Eton Pharmaceuticals, Inc. operates within the specialized realm of the pharmaceutical industry, with a dedicated focus on the development, acquisition, and commercialization of medicinal products aimed at treating rare diseases. The company's product portfolio includes ALKINDI SPRINKLE, an innovative adrenal insufficiency replacement therapy specifically tailored to children under 17 years old; Carglumic Acid, used to counteract acute and chronic hyperammonemia resulting from N-acetylglutamate Synthase deficiency; Betaine Anhydrous for managing homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

In addition to these offerings, Eton provides Zeneo hydrocortisone auto-injector as a novel solution for adrenal crises. Ever-evolving since its incorporation in 2017, Eton Pharmaceuticals continues its operations from its headquarters nestled in Deer Park, Illinois and remains consistently focused on their mission - utilizing specialized pharmaceutical expertise to improve patients' lives by addressing unmet needs in rare diseases.

Sector:
Country:United States
Industry:
Address:21925 W Field Pkwy Ste 235, Deer Park
Employees:44
Website:etonpharma.com

Pros

Orphan drug market exclusivity periods

Leveraging 505(b)(2) regulatory pathway for efficiency

Specialty pharmaceutical commercial infrastructure

Diversified product pipeline for future growth

Intellectual property protection for product portfolio

Cons

Limited total addressable market for rare disease products

High research and development expenditure requirements

Regulatory approval and market access uncertainties

Payer reimbursement challenges for high-cost therapies

Competition from other specialty pharmaceutical companies

Company	AI Score	Compare
IONSIonis Pharmaceuticals Inc
SPRBSpruce Biosciences Inc
RAREUltragenyx Pharmaceutical Inc
CRNXCrinetics Pharmaceuticals Inc
LGNDLigand Pharmaceuticals Inc

Company	AI Score	Compare
IONSIonis Pharmaceuticals Inc
SPRBSpruce Biosciences Inc
RAREUltragenyx Pharmaceutical Inc
CRNXCrinetics Pharmaceuticals Inc
LGNDLigand Pharmaceuticals Inc

ETON Stock AI Analysis